中药辅助MTX联合米非司酮保守治疗异位妊娠的疗效观察  被引量:23

Clinical observation on Chinese medicine combined with Methotrexate and Mifepristone in the treatment of ectopic pregnancy

在线阅读下载全文

作  者:姜鸿雁[1] 邱爽[1] 

机构地区:[1]湖北省十堰市中医医院妇科,湖北十堰442000

出  处:《中国医药导报》2012年第17期137-138,共2页China Medical Herald

摘  要:目的探讨中药辅助甲氨蝶呤联合米非司酮在异位妊娠保守治疗中的临床应用价值。方法将我院2009年1月~2011年1月确诊且接受保守治疗的84例异位妊娠患者随机分成实验组(42例)和对照组(42例)。对照组给予甲氨蝶呤+米非司酮治疗,实验组在此基础上再给予中药治疗。观察两组治疗后的临床疗效和不良反应发生情况,比较两组患者的平均住院时间、阴道出血停止时间、腹痛消失时间、血β-HCG恢复正常时间以及病灶包块吸收情况。结果实验组的临床疗效显著优于对照组(P<0.05);实验组的不良反应发生率明显小于对照组(P<0.05);实验组所需要的平均住院时间、阴道出血停止时间、腹痛消失时间、血β-HCG恢复正常时间均少于对照组(P<0.05);实验组的病灶包块吸收情况明显优于对照组(P<0.05)。结论临床应用中药辅助甲氨蝶呤联合米非司酮保守治疗异位妊娠的效果良好。Objective To investigate the clinical value on Chinese medicine combined with Methotrexate and Mifepristone in the treatment of ectopic pregnancy.Methods 84 patients with ectopic pregnancy admitted to hospital from January 2009 to January 2011 were randomly divided into control group(n = 42) and treatment group(n = 42).The control group was given Methotrexate and Mifepristone,but the treatment group was also given Chinese medicine.The clinical efficacy and the biochemical values in two groups were observed and compared after treatment.Results The clinical efficacy in the treatment group was significantly better than the control group(P 0.05);the incidence of adverse reactions,the hospital staying time,the vaginal bleeding stopping time,abdominal pain stopping time and blood β-HCG to the normal value time in the treatment group were significantly less than that of the control group(P 0.05);and the absorption of lesion mass in the treatment group was significantly better than that of the control group(P 0.05).Conclusion There is a significant clinical effect of Chinese medicine combined with Methotrexate and Mifepristone in the treatment of ectopic pregnancy.

关 键 词:异位妊娠 中药 甲氨蝶呤 米非司酮 

分 类 号:R714.22[医药卫生—妇产科学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象